CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Axitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03291314
NCT03291314Phase 2Completed
CompareCT.gov

Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma

Universitair Ziekenhuis Brussel·interventional·Posted Sep 25, 2017·Updated Jan 23, 2019

In Brief

A Phase 2 clinical trial evaluating Axitinib and Avelumab for Recurrent Glioblastoma (WHO-Grade IV Glioma). Completed, enrolled 52 participants across 1 site.

Detailed Summary

Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation therapy and temozolomide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma (WHO-Grade IV Glioma)
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 25, 2017
Enrollment StartMay 3, 2017
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.8 years ago

Interventions

Axitinibdrug

1\. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].

Avelumabdrug

2\. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.